DETERMINING DISEASE CAUSALITY FROM EXPERIMENTAL TOXICOLOGY STUDIES.
作者信息
Melnick Ronald L, Bucher John R
机构信息
Ronald L. Melnick is Director of Special Programs, Environmental Toxicology Program (ETP), National Toxicology Program (NTP), National Institute of Environmental Health Sciences (NIEHS); John R. Bucher is Deputy Director ETP, NTP/NIEHS.
出版信息
J Law Policy. 2005;14(1):113-133.
Abstract
摘要
相似文献
1
DETERMINING DISEASE CAUSALITY FROM EXPERIMENTAL TOXICOLOGY STUDIES.
J Law Policy. 2005;14(1):113-133.
2
Toxicology and epidemiology: improving the science with a framework for combining toxicological and epidemiological evidence to establish causal inference.
Toxicol Sci. 2011 Aug;122(2):223-34. doi: 10.1093/toxsci/kfr113. Epub 2011 May 10.
3
[Causality in occupational oncology: the toxicologist opinion].
G Ital Med Lav Ergon. 2011 Jul-Sep;33(3):310-3.
4
Modernizing the Bradford Hill criteria for assessing causal relationships in observational data.
Crit Rev Toxicol. 2018 Sep;48(8):682-712. doi: 10.1080/10408444.2018.1518404. Epub 2018 Nov 15.
5
Comments on recent discussions providing differing causation methodologies.
Hum Exp Toxicol. 2014 Jan;33(1):109-12. doi: 10.1177/0960327113491511. Epub 2013 Jun 7.
6
1.4 Comparing medicine with toxicology - a mapping of knowledge creation, concepts and basic epistemology.
Hum Exp Toxicol. 2009 Feb;28(2-3):101-4. doi: 10.1177/0960327109105759.
7
1.3 Consensus, opinion, and evidence-based science - three methods of reaching conclusions in toxicology.
Hum Exp Toxicol. 2009 Feb;28(2-3):97-9. doi: 10.1177/0960327109105758.
8
Hypothesis-Based Weight of Evidence: An Approach to Assessing Causation and its Application to Regulatory Toxicology.
Risk Anal. 2015 Jun;35(6):1114-24. doi: 10.1111/risa.12206. Epub 2014 Apr 11.
9
Determining causality and controlling disease is based on collaborative research involving multidisciplinary approaches.
Ecohealth. 2009 Sep;6(3):331-4. doi: 10.1007/s10393-010-0292-3. Epub 2010 Mar 25.
10
Causal, predictive or observational? Different understandings of key event relationships for adverse outcome pathways and their implications on practice.
Environ Toxicol Pharmacol. 2025 Jan;113:104597. doi: 10.1016/j.etap.2024.104597. Epub 2024 Nov 30.
本文引用的文献
1
Role of experimental and epidemiological evidence of carcinogenicity in the primary prevention of cancer.
Ann Ist Super Sanita. 2006;42(2):113-7.
2
The perils of relying on interested parties to evaluate scientific quality.
Am J Public Health. 2005;95 Suppl 1:S99-106. doi: 10.2105/AJPH.2004.044792.
3
A Daubert motion: a legal strategy to exclude essential scientific evidence in toxic tort litigation.
Am J Public Health. 2005;95 Suppl 1:S30-4. doi: 10.2105/AJPH.2004.046250.
4
Risk assessment of chemicals and pharmaceuticals in the pediatric population: a workshop report.
Regul Toxicol Pharmacol. 2005 Jun;42(1):83-95. doi: 10.1016/j.yrtph.2005.01.005. Epub 2005 Mar 2.
5
Extrapolations are the Achilles heel of risk assessment.
Mutat Res. 2005 May;589(3):153-7. doi: 10.1016/j.mrrev.2005.03.001. Epub 2005 Apr 25.
6
Understanding breast cancer risk -- where do we stand in 2005?
J Cell Mol Med. 2005 Jan-Mar;9(1):208-21. doi: 10.1111/j.1582-4934.2005.tb00350.x.
7
The science and practice of carcinogen identification and evaluation.
Environ Health Perspect. 2004 Sep;112(13):1269-74. doi: 10.1289/ehp.6950.
8
Relevance of animal carcinogenesis findings to human cancer predictions and prevention.
Toxicol Pathol. 2004 Mar-Apr;32 Suppl 1:40-8. doi: 10.1080/01926230490425003.
9
The genetics of cancer susceptibility: from mouse to man.
Toxicol Pathol. 2004 Mar-Apr;32 Suppl 1:26-30. doi: 10.1080/01926230490424716.
10
Pesticide testing in humans: ethics and public policy.
Environ Health Perspect. 2004 Jun;112(8):914-9. doi: 10.1289/ehp.6522.
Zotero 插件